Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE

被引:15
|
作者
Carreno J.J. [1 ]
Lodise T.P. [1 ]
机构
[1] Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, School of Pharmacy and Pharmaceutical Sciences, 106 New Scotland Ave, Albany, 12208, NY
关键词
Ceftaroline fosamil; Community-acquired pneumonia; Efficacy; Infection;
D O I
10.1007/s40121-014-0036-8
中图分类号
学科分类号
摘要
Ceftaroline fosamil (ceftaroline hereafter) is the latest addition to the armamentarium for the treatment of patients with community-acquired pneumonia (CAP). It is currently approved by the Food and Drug Administration (FDA) for community-acquired bacterial pneumonia (CABP), which is a recent FDA indication that centers on individuals with documented bacterial pneumonias that arise in the community setting. The purpose of this review is to summarize and discuss the major findings from the Phase III CAP clinical trials as well as the clinical experience with ceftaroline among patients with CAP in the “Ceftaroline Assessment Program and Teflaro® Utilization Registry” (CAPTURE). In its two Phase III CAP trials, ceftaroline was compared to ceftriaxone among adults with radiographically confirmed CAP requiring hospitalization who were classified as Pneumonia Outcomes Research Team (PORT) risk class III or IV. Among patients with CAP, clinical success at test of cure was 84.3% vs 77.7% (difference 6.6%, 95% confidence interval [CI]: 1.6–11.8%) in those treated with ceftaroline and ceftriaxone, respectively, across the two Phase III clinical trials. Among patients with a culture-confirmed CABP, day 4 response rates were numerically higher, albeit non-significant, among patients that received ceftaroline vs. ceftriaxone (69.5% for ceftaroline vs. 59.4% for ceftriaxone, difference 10.1%, 95% CI, −0.6% to 20.6%). The efficacy of ceftaroline is supported by real-world observational data from CAPTURE for patients with both CAP and CABP. In addition, the CAPTURE program afforded an opportunity to assess the outcomes of patients who were excluded or limited in the original Phase III trials in a non-comparative fashion. These underrepresented patient populations with CAP included: patients that received prior antibiotics, patients in the ICU, patients with severe renal dysfunction, and those with methicillin-resistant Staphylococcus aureus (MRSA) isolated from respiratory or blood culture. As CAPTURE is a retrospective, non-comparator convenience sample registry, all the findings need to be interpreted with caution. © 2014, The Author(s).
引用
收藏
页码:123 / 132
页数:9
相关论文
共 50 条
  • [1] Ceftaroline fosamil for community-acquired pneumonia Reply
    Zhong, Nan Shan
    Sun, Tieying
    Wilson, David
    Melnick, David
    [J]. LANCET INFECTIOUS DISEASES, 2015, 15 (09): : 999 - 1000
  • [2] Ceftaroline Fosamil For The Treatment Of Community-Acquired Bacterial Pneumonia In The Elderly: Capture Study Experience
    Udeani, G.
    Evans, J.
    Cole, P.
    Smith, A.
    Friedland, H. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [3] Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience
    Ramani, Ananthakrishnan
    Udeani, George
    Evans, John
    Jandourek, Alena
    Cole, Phillip
    Smith, Alexander
    Friedland, H. David
    [J]. JOURNAL OF CHEMOTHERAPY, 2014, 26 (04) : 229 - 234
  • [4] Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy
    DiMondi, V. Paul
    Drew, Richard H.
    Chen, Luke F.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (08) : 567 - 572
  • [5] Ceftaroline Fosamil For Treatment Of Community-Acquired Bacterial Pneumonia In The Intensive Care Unit: Capture Study Experience
    Maggiore, C.
    Vazquez, J.
    Guervil, D.
    Ramani, A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [6] Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
    Maggiore, Christy
    Vazquez, Jose A.
    Guervil, David J.
    Ramani, Ananthakrishnan
    Jandourek, Alena
    Cole, Phillip
    Friedland, H. David
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 557 - 563
  • [7] Capture: Ceftaroline Fosamil For The Treatment Of Community Acquired Bacterial Pneumonia (cabp): Year 1
    Udeani, G.
    Jandourek, A.
    Li, Y.
    Friedland, H. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [8] Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults
    Welte, Tobias
    Kantecki, Michal
    Stone, Gregory G.
    Hammond, Jennifer
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (04) : 410 - 422
  • [9] Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
    Torres, Antoni
    Bassetti, Matteo
    Welte, Tobias
    Rivolo, Simone
    Remak, Edit
    Peral, Carmen
    Charbonneau, Claudie
    Hammond, Jennifer
    Ansari, Wajeeha
    Grau, Santiago
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 148 - 155
  • [10] ECONOMIC EFFECTIVENESS OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF HOSPITALISED PATIENTS WITH PNEUMOCOCCAL COMMUNITY-ACQUIRED PNEUMONIA FROM A SOCIETAL PERSPECTIVE
    Belkova, Y. A.
    Rachina, S. A.
    Kozlov, R. S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A237 - A237